Citigroup Initiates Coverage On Madrigal Pharmaceuticals with Buy Rating, Announces Price Target of $382
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst David Lebowitz initiates coverage on Madrigal Pharmaceuticals (MDGL) with a Buy rating and sets a price target of $382.

March 06, 2024 | 10:22 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Citigroup has initiated coverage on Madrigal Pharmaceuticals with a Buy rating and a price target of $382.
Analyst ratings, especially from a reputable financial institution like Citigroup, can significantly influence investor sentiment and stock prices. A Buy rating combined with a high price target suggests a strong bullish outlook for Madrigal Pharmaceuticals, potentially leading to increased investor interest and a rise in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100